Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Filament BioSolutions Inc., a medical nutrition company, announced today a broad partnership with Ajinomoto North America, Inc., a subsidiary of Ajinomoto Co., Inc., a global manufacturer of high-quality amino acids for the pharmaceutical and food industry. The focus of this partnership is to develop and commercialize a portfolio of medical foods. Through the partnership, Filament has received financing from Ajinomoto, and will work closely with Ajinomoto’s scientists and food technologists to assist in product development, as well as to identify future opportunities for additional medical food products.
Filament has introduced two medical food product candidates into its portfolio, FB-2710 and FB-3100. Both candidates will incorporate Ajinomoto amino acids that will be formulated to address specific underlying nutritional deficiencies, resulting from a disease, in patients that are under the supervision of a physician.
“We are currently in an exciting time for the pharmaceutical, food and nutrition industries as they are merging to create a new category of science-based nutritional products,” said Dr. Thomas Cirrito, Founder and CEO of Filament BioSolutions. “This collaboration between Filament and Ajinomoto is the result of a shared vision to lead the medical food industry as we shift the clinical treatment paradigm towards addressing nutritional deficiencies as a key component of underlying disease states in order to improve patient care.”
“We believe there is a major gap in the healthcare system that we are addressing by creating evidence-based nutritional therapies. This partnership with Ajinomoto is a unique opportunity, which will provide access to their world-class scientists and further increase our capacity to develop the highest quality and most impactful products.”
Mr. Tatsuya Sato, President and COO of Ajinomoto North America remarked, “We believe this collaboration demonstrates the synergy between Ajinomoto’s 100-year history as a global leader in amino acid production and the Filament team’s innovative approach of translating our amino acid technology into the medical nutrition space. We look forward to working with Filament in the creation of the next generation of nutritional products to improve patient health.”
About Filament BioSolutions, Inc.
Filament BioSolutions, Inc. is a medical nutrition company developing a portfolio of medical foods and nutritional therapies. Filament BioSolutions is committed to the principle of evidenced-based nutrition, and is developing high-quality products that have undergone rigorous clinical trials and that will address underlying nutritional deficiencies in specific diseases to improve patient health. For more information about Filament BioSolutions, Inc., visit www.filamentbiosolutions.com
About Ajinomoto North America, Inc.
Ajinomoto North America, Inc. is a wholly owned subsidiary of Ajinomoto Co., Inc. (Ajinomoto). Ajinomoto is recognized as a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients. The company opened its first American office in New York in 1917 and has since grown and expanded its presence, establishing offices and production facilities in New Jersey, North Carolina, Iowa and Illinois. Ajinomoto North America leverages an international manufacturing, supply and distribution chain to bring the highest-grade products to customers. For additional information on Ajinomoto North America, Inc., please visit www.ajinomoto-usa.com
Jason Rosenberg Filament BioSolutions Inc. +1 (347) 532-3332 [email protected] www.filamentbiosolutions.com
